KLRA: the cash flow

MyFinsight

For the quarter ending 2026-03-31, KLRA had -$48,441K decrease in cash & cash equivalents over the period.

Cash Flow	2026-03-31
Net loss	-78,865
Depreciation and amortization expense	101
Stock-based compensation expense	3,939
Change in fair value of preferred stock tranche right liability	0
Non-cash lease expense	-293
Accretion of discounts on investments, net	1,225
Other	19
Prepaid expenses and other current assets	-42
Non-current clinical deposits	1,133
Other non-current assets	-27
Accounts payable	-495
Accrued expenses and other current liabilities	9,376
Operating lease liabilities	-282
Other non-current liabilities	-69
Net cash used in operating activities	-68,310
Purchases of marketable securities	48,448
Maturities of marketable securities	71,297
Net cash provided by (used in) investing activities	22,849
Proceeds from the exercise of stock options	57
Payments of deferred offering costs related to initial public offering	3,037
Net cash used in financing activities	-2,980
Net decrease in cash, cash equivalents and restricted cash	-48,441
Cash and cash equivalents and restricted cash at beginning of period	161,028
Cash, cash equivalents and restricted cash at end of period	112,587

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.